Chat
Hepatocellular Carcinoma Tumor Marker Panel
Copy Utility
Acceptable panel for surveillance and monitoring of hepatocellular carcinoma.
Quantitative Liquid Chromatography/Immunoassay
Refer to individual components
3-6 days
Plain red or serum separator tube.
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Refrigerated.
Plasma
After separation from cells: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 3 months (avoid repeated freeze/thaw cycles)
| Test Number |
Components |
Reference Interval |
|---|---|---|
| Alpha Fetoprotein Total | 0-15 ng/mL | |
| Alpha Fetoprotein L3 Pct | 0-9.9 percent | |
| 0081312 | Des-gamma-carboxy Prothrombin | Effective August 20, 2012 0.0 - 7.4 ng/mL |
The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably.
The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases.
Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
For pregnant females, the result is not interpretable as a tumor marker.
The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
Medication containing vitamin K preparations may cause a negative bias of the DCP values.
Medication containing vitamin K antagonist or antibiotic may cause a positive bias of the DCP values.
FDA
82107; 83951
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0081207 | Alpha Fetoprotein Total | 1834-1 |
| 0081209 | Alpha Fetoprotein L3 Pct | 42332-7 |
| 0081327 | Des-gamma-carboxy Prothrombin | 34444-0 |
- AFP
- AFP-L3 Percent
- Alpha Fetoprotein
- Alpha Fetoprotein, Total and L3 Percent Tumor Marker
- Alpha-Fetoprotein (AFP) L3 Percent and Total
- Alpha-fetoprotein, Total
- DCP
- Des-Gamma-Carboxy Prothrombin Tumor Marker
- PIVKA-II
- Total AFP
Feedback
